A flu vaccine that harnesses the messenger RNA technology that ended the COVID-19 pandemic appears increasingly likely, ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

Pfizer's mRNA flu vaccine posts promising NEJM results. Dr. Todd Ellerin of South Shore Health discusses safety, side effects ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Good morning. Because the flu shot is locked in six months early, it missed the strain now circulating through Canada – more ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...

Some scientists say this year's flu shot isn't well matched to a key strain that could spread widely in the months ahead. So, ...